Cell-Based Research for Liver and Kidney Conditions: What Is Known and What Remains Uncertain
Established care can treat underlying causes, slow disease progression and reduce complications.[17][16] Cell-based interventions for liver and kidney conditions remain investigational, and their clinical benefits and long-term risks are not yet established. This page summarizes evidence quality, safety uncertainties and Japan’s regulatory pathways.[5][9]
An independent overview of published evidence, safety uncertainties and regulatory pathways.
Scope and Publisher Disclosure
Japan Medical is an independent health-information publisher. It is not a hospital, clinic, laboratory, medical practice or referral agency. This page does not provide diagnosis, medical advice, test-result interpretation, individual eligibility assessment, provider recommendations, appointment arrangements or treatment referrals. Japan Medical does not claim physician review of this page.
AuthorJapan Medical
Published byJapan Medical
Maintained byJapan Medical
Source review and updatesJapan Medical
Editorial scopePublic research and regulatory information
Last source check28 July 2026
Source method: Japan Medical prioritizes official agencies, trial registries, systematic reviews and professional guidelines. Sources must directly support each claim and are reviewed when material evidence or regulation changes.
Key Conclusions
Five points carry the most weight on this page. Each is developed with sources in the sections that follow.
The cell-based interventions discussed on this page remain investigational.
Evidence involving liver and kidney conditions must be evaluated separately.
Changes in laboratory values do not automatically establish clinical benefit.
Study registration or plan submission is not the same as product approval.
Japan Medical provides source-based public information, not individual assessment.
Terms and Status Labels Used on This Page
Precise terms prevent misreading. The labels below are used consistently throughout the page.
Cell-based intervention
A procedure in which living cells are collected, processed and administered with the intention of producing a biological effect. The term covers many different products and study designs.
Stem cell
A cell that can renew itself and, under some conditions, develop into more specialized cell types. Different stem-cell types differ greatly in origin, behaviour and regulatory status.
Mesenchymal stromal cell (MSC)
A cell type obtained from tissues such as fat or bone marrow and studied for signalling effects in laboratory and clinical research. Research use does not imply established benefit.
Autologous
Autologous means that the source material comes from the same person who receives the intervention. It does not establish effectiveness, product quality or freedom from risk.[3]
Allogeneic
Source material that comes from a donor other than the recipient. Allogeneic products raise distinct manufacturing, consistency and immune considerations that studies must address separately.
Investigational
An intervention whose benefits and risks are still being evaluated and which has not been shown, through adequate human evidence, to provide the claimed clinical effect.[5]
Registered study
A registered study is a record in a registry. Registration does not mean that a government agency has approved the study’s safety, scientific validity or expected benefit.[2]
Submitted plan
In Japan, a provision plan filed under the Act on the Safety of Regenerative Medicine before covered cell-therapy activities are offered in research or medical practice.[11]
Publicly listed plan
A submitted plan that appears in public Ministry of Health, Labour and Welfare systems. Listing is a transparency measure and is not an evaluation of results.[13]
Marketing approval
Formal authorization allowing a regenerative medical product to be marketed, granted through the PMD Act pathway after regulatory review of submitted evidence.[14]
Conditional and time-limited approval
A Japanese pathway allowing earlier marketing of certain regenerative medical products on condition that further evidence is gathered within a defined period.[11]
Biomarker
A measurable characteristic used as an indicator of a biological process or response, such as a blood enzyme level. A biomarker is a measurement, not a health outcome by itself.[8]
Surrogate endpoint
A biomarker used to stand in for a direct clinical outcome. It substitutes reliably only when validated for that specific use, and even then may miss parts of the benefit-risk picture.[8]
Clinical outcome
A result that reflects how a person actually feels, functions or survives — for example mortality, organ failure or quality of life — rather than a laboratory measurement alone.[8]
What Established Care Can Do — Liver Conditions
Cirrhosis care focuses on treating the underlying cause and on preventing and managing complications. When the cause is effectively controlled, fibrosis improves in some people; established cirrhosis is more difficult to reverse, and improvement cannot be assumed from a laboratory marker alone.[17]
Treating the underlying cause
Antiviral medicines for chronic viral hepatitis, and direct management of alcohol-related and metabolic causes, form the foundation of cirrhosis care.[17]
Managing complications
Care includes monitoring for and treating complications of advanced disease; transplantation is evaluated for selected people with liver failure.[17]
What Established Care Can Do — Kidney Conditions
Chronic kidney disease care aims to slow progression and reduce complications through proven measures, with dialysis or transplantation reserved for kidney failure.[16]
Why Liver and Kidney Evidence Must Be Evaluated Separately
Liver and kidney diseases differ in causes and course, and the studies examining them differ in participant populations, cell types, processing methods, administration routes and endpoints. A result from a cirrhosis study is not evidence of effect in CKD, and a CKD result is not evidence of effect in liver disease. Every figure on this page states the condition, population and follow-up it describes, and no single phrase is used to claim recovery across both organs.
The two key markers used to identify and monitor chronic kidney disease are eGFR and urine albumin. CKD generally requires evidence of kidney damage or reduced kidney function lasting for more than three months.[4] Liver assessment uses a different set of measures and timeframes, which is one more reason pooled claims about “organs” mislead.
Liver and kidney studies differ in populations, methods and endpoints.
Biological Hypotheses Being Studied
What laboratory studies examine
Cell-culture work examines whether mesenchymal stromal cells release signals that affect inflammatory signalling, fibrosis-related pathways and cell behaviour in controlled conditions.
What animal studies examine
Animal models test proposed biological mechanisms such as angiogenesis, cell migration and changes in the local tissue environment after cell administration.
What these findings cannot establish
Laboratory and animal findings may provide a rationale for further study, but they do not establish that an intervention helps people feel better, function better, avoid organ failure or live longer.[5]
Why controlled human studies are needed
Human disease differs from models in cause, stage and coexisting conditions. Controlled studies are needed to separate a real effect from natural variation, co-treatment and expectation.
How Evidence Moves from Laboratory Research to Clinical Use
Clinical trials may use phases, random assignment, control groups and masking to answer different questions and reduce bias.[7] Many studied interventions never progress through every stage below.
Laboratory research
Answers whether a biological effect is plausible in cells. It cannot answer whether people benefit. Common misreading: treating a dish-level finding as a patient-level result.
Animal and preclinical research
Answers whether an effect appears in a living model and flags early hazards. It cannot predict human dose or outcomes. Common misreading: assuming model disease equals human disease.
Early human studies
Answer feasibility, dosing and short-term tolerability in small groups. Without controls they cannot separate effect from coincidence. Common misreading: reading small uncontrolled series as proof.
Controlled clinical trials
A well-designed randomized controlled trial helps determine whether an intervention causes a clinical effect rather than merely being associated with a change.[6] Common misreading: citing any trial without checking phase, size and endpoints.
Evidence synthesis and regulatory review
Systematic reviews weigh the whole body of evidence; regulators weigh benefit-risk for specific products. Common misreading: treating one favourable study as the final word.
Every Claim on This Page Is Tied to a Checkable Public Source
Registries, systematic reviews and regulator publications are linked directly at the end of the relevant sentences, so each statement can be traced back to its record.
Biomarkers, Surrogate Endpoints and Clinical Outcomes
Measurements and outcomes answer different questions.
Biomarkers
Examples include ALT, AST, albumin and bilirubin for the liver, and eGFR and urine albumin for the kidney. ALT, AST and GGT are enzymes that may change with liver or bile-duct injury; no single value proves recovery of either organ or that an experimental intervention worked.[18]
Surrogate endpoints
A surrogate endpoint may substitute for a direct outcome only when validated for that specific use. Even a validated surrogate endpoint may provide an incomplete picture of overall benefit and risk in some settings.[8]
Clinical outcomes
Examples include mortality, organ failure, hospitalization, liver-related complications, dialysis initiation, quality of life and ability to function. Clinical outcomes directly measure whether people feel better, function better or live longer. Biomarkers and surrogate endpoints do not automatically provide the same information.[8]
Safety outcomes
Examples include serious adverse events, infection, hospitalization, discontinuation and delayed adverse events. Safety results deserve the same attention as efficacy results, especially where long-term data are scarce.
Evidence Quality and Remaining Uncertainty
The most rigorous available summary for liver disease comes from a Cochrane systematic review. For CKD, the sources cited here do not support an equivalent quantitative summary.
Cochrane Evidence Snapshot: Decompensated Cirrhosis
Scale12 studies, 823 adults, examining six groups of human stem cells. The smallest study included 27 participants and the largest 219.[9]
MethodsStudies used multiple administration routes, and all 12 had design or methodological problems. The search was current to 4 October 2024.[9]
Adverse eventsSerious adverse events were reported as 74 of 366 versus 108 of 312, and non-serious adverse events as 26 of 226 versus 1 of 211. Follow-up differed by outcome and ranged from one month to 75 months.[9]
CertaintyOverall certainty was rated very low. The review could not determine with certainty the effects on mortality, serious adverse events, quality of life, complications, non-serious adverse events or liver function.[9]
These figures should not be interpreted as a confirmed treatment effect because the review rated the evidence as very uncertain and identified important limitations in design, consistency and precision.[9]
What This Page Can and Cannot Conclude About CKD
The sources cited on this page are insufficient to provide a CKD quantitative summary at the level of the cirrhosis Cochrane review. Rather than inventing matching figures — study counts, participant numbers, improvement rates or follow-up periods — this page states the boundary plainly. A phrase such as “stabilized eGFR” would require a specific cited study, with its sample, control group, time points and uncertainty, before it could appear here as more than a study-specific result.
Registration of a CKD study does not mean that its safety, scientific validity or expected benefit has been approved by the United States government.[2] Any future CKD figures added to this page must come from government agencies, formal trial results, Cochrane or other verifiable systematic reviews.
Safety and Unknowns
Risks vary by product, processing method, administration route and patient population. In the United States, FDA has received reports involving blindness, tumour formation, infections and other harms associated with some unapproved regenerative medicine products.[3]
Source-related risks
A product recovered from a person’s own body should not automatically be described as safe.[3] Donor-derived products add screening and consistency questions of their own.
Processing and manufacturing risks
Cell handling introduces risks of contamination and product variability between batches, facilities and protocols. These risks exist regardless of how the source material was obtained.
Collection and administration risks
Collection-site reactions and administration reactions, including infection and unwanted inflammatory responses, are procedure-related risks that studies must track and report.
Biological risks
Living cells can behave unpredictably. Unwanted immune or inflammatory responses, unintended tissue formation and abnormal growth are biological risks examined in safety assessment.
Long-term and evidence-gap risks
Delayed adverse events may not appear in short follow-up. A further risk is indirect: pursuing an unproven intervention can delay established care that slows disease progression.
Public communication should convey uncertainty about the safety, reliability and efficacy of potential stem-cell applications.[10]
Two Separate Systems, Two Different Meanings
Plan submission under one Japanese pathway and product approval under the other are not interchangeable labels — the distinction is explained below.
Japan Uses Separate Pathways for Medical Practice and Product Approval
Japan’s Act on the Safety of Regenerative Medicine and the PMD Act are distinct regulatory frameworks that came into effect in November 2014.[11] The ASRM applies to covered cell-therapy activities in research and medical practice, while the PMD Act regulates commercialization of regenerative medical products.[11]
ASRM — practice pathway
Covers specified cell-therapy activities in research and medical practice. Providers prepare provision plans that undergo committee review and submission, and certain plan information becomes publicly searchable. A submitted or publicly listed provision plan must not be described as PMDA marketing approval.[11]
PMD Act — product pathway
Governs commercialization of regenerative medical products, including marketing approval, published approved-product information and review reports. A conditional and time-limited route allows earlier marketing of certain products while further evidence is gathered.[14][15]
Public records support verification of a stated regulatory status. A listing does not by itself establish efficacy, endorsement or suitability for an individual. On this page, “submitted”, “filed” or “listed” refer to the ASRM pathway, and “approval” refers only to PMD Act marketing authorization.
Practice-pathway plans and product-pathway approvals live in separate public systems.
How Institution and Regulatory Claims Are Described
This page names institutions only as they appear in official records, and states the specific role each record assigns. The following rules govern every such mention:
A study location is never rewritten as a partner hospital.
A plan submitter is never rewritten as an approved provider.
A product authorization holder is never rewritten as a treatment partner.
Committee review is never rewritten as government endorsement.
A study registration number is never rewritten as a product approval number.
“Partner”, “affiliated” or “network” appear only with official proof of the relationship.
No hospital or clinic addresses, maps, directions or phone numbers are added. Official locations are cited only when needed to understand a specific record.
Any third-party identifier states its owner, recording body, status and the date it was checked.
Study locations may appear in public trial records, but their presence does not establish that Japan Medical has a relationship with the listed institution.[12]
Official records are quoted with the exact role each record assigns.
How Japan Medical Selects and Updates Sources
Government and regulatory-agency material is preferred for legal status, public trial registries for registration status, systematic reviews for evidence summaries, and professional research guidelines for scientific communication standards. Every source must directly support the sentence it sits next to; dynamic records such as registries carry an access or review date. Helpful content should provide a substantial account of the topic, clear sourcing and accurate information about who created it.[1]
The displayed modification date changes only when the substance of the page changes — never merely to appear fresh. Readers may submit factual corrections through the existing contact channel by identifying the sentence, the source and the proposed correction. Japan Medical does not interpret personal test results or assess individual eligibility.
Sources are selected for direct relevance to each claim and reviewed when records change.
Questions About Scope, Sources and Corrections
What information does Japan Medical not provide?
Japan Medical does not provide diagnosis, medical advice, test-result interpretation, personal eligibility assessment, provider recommendations, appointment arrangements or referrals. This page covers public research and regulatory information only.
How often are sources checked?
Japan Medical checks sources when material evidence, regulatory information or cited public records change. The displayed source-review date describes the latest editorial check and does not mean every underlying study was published on that date.
How can a factual correction be submitted?
Readers may contact Japan Medical through the existing contact channel and identify the sentence, source and proposed correction. Japan Medical reviews correction requests against the relevant public record.
Cited Sources
- Google Search Central — Creating helpful, reliable, people-first content.
- ClinicalTrials.gov — Disclaimer.
- U.S. Food and Drug Administration — Important patient and consumer information about regenerative medicine therapies.
- NIDDK — Identify and evaluate CKD.
- International Society for Stem Cell Research — Clinical translation of stem cell-based interventions.
- U.S. National Institutes of Health — Understanding clinical studies.
- ClinicalTrials.gov — Learn about studies.
- U.S. Food and Drug Administration — FDA facts: biomarkers and surrogate endpoints.
- Cochrane — Human stem cells for advanced liver disease in adults.
- International Society for Stem Cell Research — Communications guidelines.
- PMDA — Regenerative Medical Products Information.
- Japan Registry of Clinical Trials — jRCT.
- Ministry of Health, Labour and Welfare (Japan) — Published provision plans.
- PMDA — Approved regenerative medical products.
- PMDA — Review reports.
- NIDDK — Slow CKD progression and reduce complications.
- NIDDK — Cirrhosis treatment.
- MedlinePlus — Liver function tests.
Need Help Navigating the Sources?
Send Japan Medical a general question about the references, definitions or public records used on this page. Personal assessments and service recommendations are outside the scope of this page.
General source and reference enquiries only.